CA2575760A1 - Betaines specifiques et leurs utilisations - Google Patents

Betaines specifiques et leurs utilisations Download PDF

Info

Publication number: CA2575760A1
Authority: CA; Canada
Prior art keywords: composition; betaine; solution; pharmaceutical; final concentration
Prior art date: 2003-08-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002575760A

Other languages

English (en)

Inventor

Jallal Messadek

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-04

Filing date

2004-08-03

Publication date

2005-02-10

2003-08-04 Priority claimed from US10/635,048 external-priority patent/US7608640B2/en

2004-08-03 Application filed by Individual filed Critical Individual

2005-02-10 Publication of CA2575760A1 publication Critical patent/CA2575760A1/fr

Status Abandoned legal-status Critical Current

Links

KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims abstract description 459
229960003237 betaine Drugs 0.000 claims abstract description 260
239000002904 solvent Substances 0.000 claims abstract description 41
239000000243 solution Substances 0.000 claims description 192
239000000203 mixture Substances 0.000 claims description 121
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 103
229960002897 heparin Drugs 0.000 claims description 103
229920000669 heparin Polymers 0.000 claims description 103
238000000034 method Methods 0.000 claims description 70
230000000694 effects Effects 0.000 claims description 68
150000001875 compounds Chemical class 0.000 claims description 61
150000003839 salts Chemical class 0.000 claims description 51
230000008569 process Effects 0.000 claims description 45
239000003795 chemical substances by application Substances 0.000 claims description 44
XEKSTYNIJLDDAZ-JASSWCPGSA-D decasodium;(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5r,6r)-6-[(2r,3s,4s,5r,6r)-2-carboxylato-4-hydroxy-6-[(2r,3s,4r,5r,6s)-4-hydroxy-6-methoxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-5-sulfonatooxyoxan-3-yl]oxy-5-(sulfonatoamino)-4-sulfonatooxy-2-(sul Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].O[C@@H]1[C@@H](NS([O-])(=O)=O)[C@@H](OC)O[C@H](COS([O-])(=O)=O)[C@H]1O[C@H]1[C@H](OS([O-])(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS([O-])(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS([O-])(=O)=O)O4)NS([O-])(=O)=O)[C@H](O3)C([O-])=O)O)[C@@H](COS([O-])(=O)=O)O2)NS([O-])(=O)=O)[C@H](C([O-])=O)O1 XEKSTYNIJLDDAZ-JASSWCPGSA-D 0.000 claims description 44
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 40
230000000740 bleeding effect Effects 0.000 claims description 34
239000002552 dosage form Substances 0.000 claims description 34
229940104697 arixtra Drugs 0.000 claims description 32
-1 polyethylene Polymers 0.000 claims description 30
239000007864 aqueous solution Substances 0.000 claims description 29
238000004659 sterilization and disinfection Methods 0.000 claims description 27
210000004369 blood Anatomy 0.000 claims description 26
PGWTYMLATMNCCZ-UHFFFAOYSA-M azure A Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 PGWTYMLATMNCCZ-UHFFFAOYSA-M 0.000 claims description 25
239000008194 pharmaceutical composition Substances 0.000 claims description 25
230000001858 anti-Xa Effects 0.000 claims description 24
239000008280 blood Substances 0.000 claims description 24
238000002835 absorbance Methods 0.000 claims description 22
108010055460 bivalirudin Proteins 0.000 claims description 22
OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 claims description 22
230000000144 pharmacologic effect Effects 0.000 claims description 22
238000001914 filtration Methods 0.000 claims description 21
108010007267 Hirudins Proteins 0.000 claims description 17
102000007625 Hirudins Human genes 0.000 claims description 17
230000010100 anticoagulation Effects 0.000 claims description 17
230000004888 barrier function Effects 0.000 claims description 16
229960001500 bivalirudin Drugs 0.000 claims description 15
238000002360 preparation method Methods 0.000 claims description 15
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 14
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 14
229960003856 argatroban Drugs 0.000 claims description 14
KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 claims description 14
229940006607 hirudin Drugs 0.000 claims description 14
239000011591 potassium Chemical class 0.000 claims description 14
229910052700 potassium Chemical class 0.000 claims description 14
239000011734 sodium Substances 0.000 claims description 14
229910052708 sodium Inorganic materials 0.000 claims description 14
ZXIBCJHYVWYIKI-PZJWPPBQSA-N ximelagatran Chemical compound C1([C@@H](NCC(=O)OCC)C(=O)N2[C@@H](CC2)C(=O)NCC=2C=CC(=CC=2)C(\N)=N\O)CCCCC1 ZXIBCJHYVWYIKI-PZJWPPBQSA-N 0.000 claims description 14
229960001522 ximelagatran Drugs 0.000 claims description 14
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 13
229960003661 fondaparinux sodium Drugs 0.000 claims description 13
WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims description 13
239000011777 magnesium Chemical class 0.000 claims description 13
229910052749 magnesium Inorganic materials 0.000 claims description 13
238000001728 nano-filtration Methods 0.000 claims description 13
239000002510 pyrogen Substances 0.000 claims description 13
230000002441 reversible effect Effects 0.000 claims description 11
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
MVPQUSQUURLQKF-MCPDASDXSA-E nonasodium;(2s,3s,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3s,4s,5r,6r)-2-carboxylato-4,5-dimethoxy-6-[(2r,3r,4s,5r,6s)-6-methoxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-4,5-di Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)O[C@@H]1[C@@H](OS([O-])(=O)=O)[C@@H](OC)O[C@H](COS([O-])(=O)=O)[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@@H]2[C@@H]([C@@H](OS([O-])(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](OC)[C@H](O[C@@H]4[C@@H]([C@@H](OC)[C@H](OC)[C@@H](COS([O-])(=O)=O)O4)OC)[C@H](O3)C([O-])=O)OC)[C@@H](COS([O-])(=O)=O)O2)OS([O-])(=O)=O)[C@H](C([O-])=O)O1 MVPQUSQUURLQKF-MCPDASDXSA-E 0.000 claims description 9
229920001542 oligosaccharide Polymers 0.000 claims description 9
150000002482 oligosaccharides Chemical class 0.000 claims description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
229950001711 idraparinux sodium Drugs 0.000 claims description 8
230000001954 sterilising effect Effects 0.000 claims description 8
239000003868 thrombin inhibitor Substances 0.000 claims description 8
LJCBAPRMNYSDOP-LVCYMWGESA-N (2s)-3-(7-carbamimidoylnaphthalen-2-yl)-2-[4-[(3s)-1-ethanimidoylpyrrolidin-3-yl]oxyphenyl]propanoic acid;hydron;chloride;pentahydrate Chemical compound O.O.O.O.O.Cl.C1N(C(=N)C)CC[C@@H]1OC1=CC=C([C@H](CC=2C=C3C=C(C=CC3=CC=2)C(N)=N)C(O)=O)C=C1 LJCBAPRMNYSDOP-LVCYMWGESA-N 0.000 claims description 7
BISKEOIROPAOGY-RXQQAGQTSA-N (2s)-n-[(2s)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(2r)-2-(methylamino)-3-phenylpropanoyl]pyrrolidine-2-carboxamide;sulfuric acid Chemical compound OS(O)(=O)=O.C([C@@H](NC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C=O)C1=CC=CC=C1 BISKEOIROPAOGY-RXQQAGQTSA-N 0.000 claims description 7
CDPROXZBMHOBTQ-SJORKVTESA-N 2-[[(2r)-3-cyclohexyl-1-[(2s)-2-[3-(diaminomethylideneamino)propylcarbamoyl]piperidin-1-yl]-1-oxopropan-2-yl]amino]acetic acid Chemical compound NC(N)=NCCCNC(=O)[C@@H]1CCCCN1C(=O)[C@H](NCC(O)=O)CC1CCCCC1 CDPROXZBMHOBTQ-SJORKVTESA-N 0.000 claims description 7
108010039209 Blood Coagulation Factors Proteins 0.000 claims description 7
102000015081 Blood Coagulation Factors Human genes 0.000 claims description 7
229940003354 angiomax Drugs 0.000 claims description 7
239000003114 blood coagulation factor Substances 0.000 claims description 7
229950009814 efegatran Drugs 0.000 claims description 7
108010078659 efegatran Proteins 0.000 claims description 7
239000007972 injectable composition Substances 0.000 claims description 7
229950003291 inogatran Drugs 0.000 claims description 7
DKWNMCUOEDMMIN-PKOBYXMFSA-N melagatran Chemical compound C1=CC(C(=N)N)=CC=C1CNC(=O)[C@H]1N(C(=O)[C@H](NCC(O)=O)C2CCCCC2)CC1 DKWNMCUOEDMMIN-PKOBYXMFSA-N 0.000 claims description 7
229960002137 melagatran Drugs 0.000 claims description 7
102100022641 Coagulation factor IX Human genes 0.000 claims description 6
102100023804 Coagulation factor VII Human genes 0.000 claims description 6
229940123900 Direct thrombin inhibitor Drugs 0.000 claims description 6
108010076282 Factor IX Proteins 0.000 claims description 6
108010023321 Factor VII Proteins 0.000 claims description 6
229960004222 factor ix Drugs 0.000 claims description 6
229940012413 factor vii Drugs 0.000 claims description 6
230000002008 hemorrhagic effect Effects 0.000 claims description 6
238000001471 micro-filtration Methods 0.000 claims description 6
238000007789 sealing Methods 0.000 claims description 6
238000003860 storage Methods 0.000 claims description 6
238000000108 ultra-filtration Methods 0.000 claims description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 5
239000004698 Polyethylene Substances 0.000 claims description 5
238000011049 filling Methods 0.000 claims description 5
229910052760 oxygen Inorganic materials 0.000 claims description 5
239000001301 oxygen Substances 0.000 claims description 5
238000009928 pasteurization Methods 0.000 claims description 5
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
229940102223 injectable solution Drugs 0.000 claims description 4
229960004408 lepirudin Drugs 0.000 claims description 4
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
239000002202 Polyethylene glycol Substances 0.000 claims description 3
230000003750 conditioning effect Effects 0.000 claims description 3
238000001035 drying Methods 0.000 claims description 3
239000004009 herbicide Substances 0.000 claims description 3
239000000575 pesticide Substances 0.000 claims description 3
229920001223 polyethylene glycol Polymers 0.000 claims description 3
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 2
239000005977 Ethylene Substances 0.000 claims description 2
239000004743 Polypropylene Substances 0.000 claims description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
125000004429 atom Chemical group 0.000 claims description 2
229920001577 copolymer Polymers 0.000 claims description 2
239000002158 endotoxin Substances 0.000 claims description 2
229910001385 heavy metal Inorganic materials 0.000 claims description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 2
125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
239000005022 packaging material Substances 0.000 claims description 2
239000004417 polycarbonate Substances 0.000 claims description 2
229920000515 polycarbonate Polymers 0.000 claims description 2
229920000573 polyethylene Polymers 0.000 claims description 2
229920001155 polypropylene Polymers 0.000 claims description 2
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims description 2
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 2
XYWBJDRHGNULKG-OUMQNGNKSA-N desirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 XYWBJDRHGNULKG-OUMQNGNKSA-N 0.000 claims 1
229960000296 desirudin Drugs 0.000 claims 1
108010073652 desirudin Proteins 0.000 claims 1
OTQCKZUSUGYWBD-BRHMIFOHSA-N lepirudin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)[C@@H](C)O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 OTQCKZUSUGYWBD-BRHMIFOHSA-N 0.000 claims 1
229920002994 synthetic fiber Polymers 0.000 claims 1
KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 abstract 2
241000700159 Rattus Species 0.000 description 60
238000012360 testing method Methods 0.000 description 50
208000032843 Hemorrhage Diseases 0.000 description 38
208000034158 bleeding Diseases 0.000 description 33
231100000319 bleeding Toxicity 0.000 description 32
239000003146 anticoagulant agent Substances 0.000 description 21
229960000610 enoxaparin Drugs 0.000 description 21
239000000729 antidote Substances 0.000 description 20
239000003814 drug Substances 0.000 description 20
238000011282 treatment Methods 0.000 description 18
229940079593 drug Drugs 0.000 description 17
150000002148 esters Chemical class 0.000 description 15
241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 13
235000021536 Sugar beet Nutrition 0.000 description 13
239000002243 precursor Substances 0.000 description 12
238000004519 manufacturing process Methods 0.000 description 11
239000012528 membrane Substances 0.000 description 11
230000001225 therapeutic effect Effects 0.000 description 11
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 11
241001465754 Metazoa Species 0.000 description 10
229940127219 anticoagulant drug Drugs 0.000 description 10
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
230000002785 anti-thrombosis Effects 0.000 description 9
FIBJDTSHOUXTKV-BRHMIFOHSA-N lepirudin Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)CNC2=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1)C(C)C)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O FIBJDTSHOUXTKV-BRHMIFOHSA-N 0.000 description 9
229940118179 lovenox Drugs 0.000 description 9
239000000463 material Substances 0.000 description 9
210000002381 plasma Anatomy 0.000 description 9
239000011550 stock solution Substances 0.000 description 9
208000007536 Thrombosis Diseases 0.000 description 8
230000015556 catabolic process Effects 0.000 description 8
238000006731 degradation reaction Methods 0.000 description 8
238000002474 experimental method Methods 0.000 description 8
239000003755 preservative agent Substances 0.000 description 8
206010040047 Sepsis Diseases 0.000 description 7
239000000654 additive Substances 0.000 description 7
238000003556 assay Methods 0.000 description 7
230000015271 coagulation Effects 0.000 description 7
238000005345 coagulation Methods 0.000 description 7
238000001990 intravenous administration Methods 0.000 description 7
HRSYWPMGIIAQIW-UHFFFAOYSA-N 5-bromo-2,3-dihydro-1,4-benzodioxine-7-carbaldehyde Chemical compound O1CCOC2=C1C=C(C=O)C=C2Br HRSYWPMGIIAQIW-UHFFFAOYSA-N 0.000 description 6
206010051055 Deep vein thrombosis Diseases 0.000 description 6
230000001154 acute effect Effects 0.000 description 6
230000027455 binding Effects 0.000 description 6
238000006386 neutralization reaction Methods 0.000 description 6
239000002245 particle Substances 0.000 description 6
239000012602 primary packaging material Substances 0.000 description 6
239000000047 product Substances 0.000 description 6
238000001356 surgical procedure Methods 0.000 description 6
206010061218 Inflammation Diseases 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
239000013543 active substance Substances 0.000 description 5
229960005153 enoxaparin sodium Drugs 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
230000004054 inflammatory process Effects 0.000 description 5
230000000704 physical effect Effects 0.000 description 5
239000000126 substance Substances 0.000 description 5
CIJQTPFWFXOSEO-NDMITSJXSA-J tetrasodium;(2r,3r,4s)-2-[(2r,3s,4r,5r,6s)-5-acetamido-6-[(1r,2r,3r,4r)-4-[(2r,3s,4r,5r,6r)-5-acetamido-6-[(4r,5r,6r)-2-carboxylato-4,5-dihydroxy-6-[[(1r,3r,4r,5r)-3-hydroxy-4-(sulfonatoamino)-6,8-dioxabicyclo[3.2.1]octan-2-yl]oxy]oxan-3-yl]oxy-2-(hydroxy Chemical compound [Na+].[Na+].[Na+].[Na+].O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1O)NC(C)=O)O[C@@H]1C(C[C@H]([C@@H]([C@H]1O)O)O[C@@H]1[C@@H](CO)O[C@H](OC2C(O[C@@H](OC3[C@@H]([C@@H](NS([O-])(=O)=O)[C@@H]4OC[C@H]3O4)O)[C@H](O)[C@H]2O)C([O-])=O)[C@H](NC(C)=O)[C@H]1C)C([O-])=O)[C@@H]1OC(C([O-])=O)=C[C@H](O)[C@H]1O CIJQTPFWFXOSEO-NDMITSJXSA-J 0.000 description 5
241000196324 Embryophyta Species 0.000 description 4
229920002683 Glycosaminoglycan Polymers 0.000 description 4
206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 4
206010020772 Hypertension Diseases 0.000 description 4
208000010378 Pulmonary Embolism Diseases 0.000 description 4
206010047249 Venous thrombosis Diseases 0.000 description 4
239000002253 acid Substances 0.000 description 4
230000002776 aggregation Effects 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
230000000875 corresponding effect Effects 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
210000003414 extremity Anatomy 0.000 description 4
KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 description 4
239000011521 glass Substances 0.000 description 4
238000010438 heat treatment Methods 0.000 description 4
230000023597 hemostasis Effects 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
208000014674 injury Diseases 0.000 description 4
239000007788 liquid Substances 0.000 description 4
229940127215 low-molecular weight heparin Drugs 0.000 description 4
239000006186 oral dosage form Substances 0.000 description 4
208000007232 portal hypertension Diseases 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
239000001509 sodium citrate Substances 0.000 description 4
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
235000016068 Berberis vulgaris Nutrition 0.000 description 3
241000335053 Beta vulgaris Species 0.000 description 3
206010053567 Coagulopathies Diseases 0.000 description 3
206010015548 Euthanasia Diseases 0.000 description 3
108010074860 Factor Xa Proteins 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
206010030113 Oedema Diseases 0.000 description 3
IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 3
108090000190 Thrombin Proteins 0.000 description 3
238000004220 aggregation Methods 0.000 description 3
230000002744 anti-aggregatory effect Effects 0.000 description 3
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
229950010582 betaine anhydrous Drugs 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
238000010241 blood sampling Methods 0.000 description 3
239000000872 buffer Substances 0.000 description 3
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
238000000576 coating method Methods 0.000 description 3
238000011109 contamination Methods 0.000 description 3
230000020764 fibrinolysis Effects 0.000 description 3
229960001318 fondaparinux Drugs 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
229910052500 inorganic mineral Inorganic materials 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
230000003902 lesion Effects 0.000 description 3
150000007524 organic acids Chemical class 0.000 description 3
239000012466 permeate Substances 0.000 description 3
210000003240 portal vein Anatomy 0.000 description 3
230000002265 prevention Effects 0.000 description 3
239000012465 retentate Substances 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
229960004072 thrombin Drugs 0.000 description 3
230000008733 trauma Effects 0.000 description 3
CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
102000003886 Glycoproteins Human genes 0.000 description 2
108090000288 Glycoproteins Proteins 0.000 description 2
208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 2
208000031220 Hemophilia Diseases 0.000 description 2
208000009292 Hemophilia A Diseases 0.000 description 2
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
241000700157 Rattus norvegicus Species 0.000 description 2
241000219315 Spinacia Species 0.000 description 2
235000009337 Spinacia oleracea Nutrition 0.000 description 2
241000209140 Triticum Species 0.000 description 2
235000021307 Triticum Nutrition 0.000 description 2
206010046996 Varicose vein Diseases 0.000 description 2
229960001138 acetylsalicylic acid Drugs 0.000 description 2
230000004913 activation Effects 0.000 description 2
239000008186 active pharmaceutical agent Substances 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
238000013019 agitation Methods 0.000 description 2
230000003042 antagnostic effect Effects 0.000 description 2
230000001093 anti-cancer Effects 0.000 description 2
229960004676 antithrombotic agent Drugs 0.000 description 2
230000003190 augmentative effect Effects 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000003593 chromogenic compound Substances 0.000 description 2
208000037998 chronic venous disease Diseases 0.000 description 2
230000035602 clotting Effects 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
239000000356 contaminant Substances 0.000 description 2
229940088679 drug related substance Drugs 0.000 description 2
NJZRLXNBGZBREL-UHFFFAOYSA-N glycine betaine hydrate Chemical compound [OH-].C[N+](C)(C)CC(O)=O NJZRLXNBGZBREL-UHFFFAOYSA-N 0.000 description 2
238000001631 haemodialysis Methods 0.000 description 2
208000009429 hemophilia B Diseases 0.000 description 2
238000001802 infusion Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
238000010255 intramuscular injection Methods 0.000 description 2
239000007927 intramuscular injection Substances 0.000 description 2
210000004731 jugular vein Anatomy 0.000 description 2
210000002414 leg Anatomy 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
230000004089 microcirculation Effects 0.000 description 2
239000011707 mineral Substances 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
238000002156 mixing Methods 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
235000016709 nutrition Nutrition 0.000 description 2
230000007170 pathology Effects 0.000 description 2
210000005164 penile vein Anatomy 0.000 description 2
230000002572 peristaltic effect Effects 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
230000035935 pregnancy Effects 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
235000013772 propylene glycol Nutrition 0.000 description 2
229960004063 propylene glycol Drugs 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
238000005070 sampling Methods 0.000 description 2
FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
KYITYFHKDODNCQ-UHFFFAOYSA-M sodium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [Na+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 KYITYFHKDODNCQ-UHFFFAOYSA-M 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
238000004611 spectroscopical analysis Methods 0.000 description 2
208000000995 spontaneous abortion Diseases 0.000 description 2
150000005846 sugar alcohols Polymers 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
230000009424 thromboembolic effect Effects 0.000 description 2
230000002885 thrombogenetic effect Effects 0.000 description 2
230000002792 vascular Effects 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
201000002282 venous insufficiency Diseases 0.000 description 2
229960002647 warfarin sodium Drugs 0.000 description 2
MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 1
ARXJGSRGQADJSQ-UHFFFAOYSA-N 1-methoxypropan-2-ol Chemical class COCC(C)O ARXJGSRGQADJSQ-UHFFFAOYSA-N 0.000 description 1
MHOFGBJTSNWTDT-UHFFFAOYSA-M 2-[n-ethyl-4-[(6-methoxy-3-methyl-1,3-benzothiazol-3-ium-2-yl)diazenyl]anilino]ethanol;methyl sulfate Chemical compound COS([O-])(=O)=O.C1=CC(N(CCO)CC)=CC=C1N=NC1=[N+](C)C2=CC=C(OC)C=C2S1 MHOFGBJTSNWTDT-UHFFFAOYSA-M 0.000 description 1
RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
VTDOEFXTVHCAAM-UHFFFAOYSA-N 4-methylpent-3-ene-1,2,3-triol Chemical compound CC(C)=C(O)C(O)CO VTDOEFXTVHCAAM-UHFFFAOYSA-N 0.000 description 1
206010000234 Abortion spontaneous Diseases 0.000 description 1
206010001488 Aggression Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010002388 Angina unstable Diseases 0.000 description 1
208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
208000005189 Embolism Diseases 0.000 description 1
208000001951 Fetal Death Diseases 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
206010017711 Gangrene Diseases 0.000 description 1
235000008100 Ginkgo biloba Nutrition 0.000 description 1
244000194101 Ginkgo biloba Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
206010020365 Homocystinuria Diseases 0.000 description 1
208000033892 Hyperhomocysteinemia Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
108010090444 Innovin Proteins 0.000 description 1
206010022562 Intermittent claudication Diseases 0.000 description 1
208000022120 Jeavons syndrome Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
208000001145 Metabolic Syndrome Diseases 0.000 description 1
208000034486 Multi-organ failure Diseases 0.000 description 1
208000010718 Multiple Organ Failure Diseases 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
206010030043 Ocular hypertension Diseases 0.000 description 1
206010030209 Oesophageal varices Diseases 0.000 description 1
206010033307 Overweight Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
108091006629 SLC13A2 Proteins 0.000 description 1
108010077895 Sarcosine Proteins 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
201000001880 Sexual dysfunction Diseases 0.000 description 1
229940122388 Thrombin inhibitor Drugs 0.000 description 1
206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
208000001435 Thromboembolism Diseases 0.000 description 1
108010000499 Thromboplastin Proteins 0.000 description 1
102000002262 Thromboplastin Human genes 0.000 description 1
201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
208000007814 Unstable Angina Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
238000012084 abdominal surgery Methods 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000016571 aggressive behavior Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000008431 aliphatic amides Chemical class 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
239000004411 aluminium Substances 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
238000002399 angioplasty Methods 0.000 description 1
238000000137 annealing Methods 0.000 description 1
230000003429 anti-cardiolipin effect Effects 0.000 description 1
230000002364 anti-haemorrhagic effect Effects 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
229940127226 anticholesterol agent Drugs 0.000 description 1
229940075522 antidotes Drugs 0.000 description 1
229940030225 antihemorrhagics Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
239000002585 base Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
238000010256 biochemical assay Methods 0.000 description 1
229940093797 bioflavonoids Drugs 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
235000015895 biscuits Nutrition 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
208000015294 blood coagulation disease Diseases 0.000 description 1
239000001045 blue dye Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
229920005556 chlorobutyl Polymers 0.000 description 1
229960002242 chlorocresol Drugs 0.000 description 1
201000002816 chronic venous insufficiency Diseases 0.000 description 1
230000004087 circulation Effects 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
239000004927 clay Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
230000006378 damage Effects 0.000 description 1
239000008232 de-aerated water Substances 0.000 description 1
231100000517 death Toxicity 0.000 description 1
230000034994 death Effects 0.000 description 1
238000005034 decoration Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
108700003601 dimethylglycine Proteins 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
150000004862 dioxolanes Chemical class 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
210000003989 endothelium vascular Anatomy 0.000 description 1
230000006353 environmental stress Effects 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
231100000479 fetal death Toxicity 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000004907 flux Effects 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
229940087051 fragmin Drugs 0.000 description 1
238000002682 general surgery Methods 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000000025 haemostatic effect Effects 0.000 description 1
238000002615 hemofiltration Methods 0.000 description 1
208000031169 hemorrhagic disease Diseases 0.000 description 1
208000014617 hemorrhoid Diseases 0.000 description 1
238000011540 hip replacement Methods 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
239000003501 hydroponics Substances 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
229910001504 inorganic chloride Inorganic materials 0.000 description 1
201000004332 intermediate coronary syndrome Diseases 0.000 description 1
208000021156 intermittent vascular claudication Diseases 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
238000013150 knee replacement Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
108010002230 lepirudin Proteins 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
239000003055 low molecular weight heparin Substances 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
239000012982 microporous membrane Substances 0.000 description 1
208000015994 miscarriage Diseases 0.000 description 1
239000011259 mixed solution Substances 0.000 description 1
235000013379 molasses Nutrition 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
DDJZTXMTVGFOMH-UHFFFAOYSA-N n,2-dihydroxy-2-methylbutanamide Chemical compound CCC(C)(O)C(=O)NO DDJZTXMTVGFOMH-UHFFFAOYSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
229940127234 oral contraceptive Drugs 0.000 description 1
239000003539 oral contraceptive agent Substances 0.000 description 1
230000004768 organ dysfunction Effects 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
238000012829 orthopaedic surgery Methods 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920000570 polyether Polymers 0.000 description 1
239000008389 polyethoxylated castor oil Substances 0.000 description 1
229940068918 polyethylene glycol 400 Drugs 0.000 description 1
229920000151 polyglycol Polymers 0.000 description 1
239000010695 polyglycol Substances 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
238000004321 preservation Methods 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
238000007639 printing Methods 0.000 description 1
239000003805 procoagulant Substances 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
239000008213 purified water Substances 0.000 description 1
HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
150000004040 pyrrolidinones Chemical class 0.000 description 1
238000011084 recovery Methods 0.000 description 1
229940030915 refludan Drugs 0.000 description 1
238000009877 rendering Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
229940043230 sarcosine Drugs 0.000 description 1
230000037390 scarring Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
231100000872 sexual dysfunction Toxicity 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
230000003019 stabilising effect Effects 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000008718 systemic inflammatory response Effects 0.000 description 1
230000001732 thrombotic effect Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 1
229960002622 triacetin Drugs 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
208000027185 varicose disease Diseases 0.000 description 1
208000037997 venous disease Diseases 0.000 description 1
239000008215 water for injection Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CA002575760A 2003-08-04 2004-08-03 Betaines specifiques et leurs utilisations Abandoned CA2575760A1 (fr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US10/635,048		2003-08-04
US10/635,048 US7608640B2 (en)	1999-03-02	2003-08-04	Glycine betaine and its use
BEPCT/BE04/000043		2004-03-23
BEPCT/BE04/00043		2004-03-23
PCT/BE2004/000110 WO2005011645A2 (fr)	2003-08-04	2004-08-03	Betaines specifiques et leurs utilisations

Publications (1)

Publication Number	Publication Date
CA2575760A1 true CA2575760A1 (fr)	2005-02-10

Family

ID=37594137

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002575760A Abandoned CA2575760A1 (fr)	2003-08-04	2004-08-03	Betaines specifiques et leurs utilisations

Country Status (2)

Country	Link
CA (1)	CA2575760A1 (fr)
WO (1)	WO2005011645A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE1015608A6 (fr)	2003-07-15	2005-06-07	Messadek Jallal	Traitement des arterites.
WO2006050581A2 (fr) *	2004-11-10	2006-05-18	Jallal Messadek	Betaine en tant qu'agent de lutte contre des maladies transmises par des arthropodes ou des moustiques
WO2006086856A1 (fr)	2005-02-15	2006-08-24	Messadek, Jallal	Compositions therapeutiques combinees et leurs procedes d’utilisation
CN101180073A (zh)	2005-04-27	2008-05-14	贾拉尔·梅萨德克	胰岛素组合
US20070190057A1 (en)	2006-01-23	2007-08-16	Jian Wu	Methods for modulating mannose content of recombinant proteins
WO2009065193A1 (fr) *	2007-11-21	2009-05-28	Jallal Messadek	Traitement de la résistance à l'aspirine par de la bétaïne et/ou de la mélasse enrichie en bétaïne
GB2465814B (en) *	2008-06-19	2011-10-26	Tarig Sayed Mustafa Arbab	Method,composition and device for the treatment of enzymes and saccharides disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE1012495A3 (fr) *	1999-03-02	2000-11-07	Messadek Jallal	La glycine-betaine pour son usage antithrombotique.
DK1408949T3 (da) *	2001-02-05	2008-04-28	Jallal Messadek	Glycinbetain og dets brugområde for opfindelsen

2004
- 2004-08-03 CA CA002575760A patent/CA2575760A1/fr not_active Abandoned
- 2004-08-03 WO PCT/BE2004/000110 patent/WO2005011645A2/fr not_active Ceased

Also Published As

Publication number	Publication date
WO2005011645A8 (fr)	2006-05-11
WO2005011645A2 (fr)	2005-02-10
WO2005011645A3 (fr)	2005-04-14

Publication	Publication Date	Title
US20090286881A1 (en)	2009-11-19	Selected betaines and their uses
US6855734B2 (en)	2005-02-15	Glycine betaine and its use
US5608038A (en)	1997-03-04	Highly concentrated immunoglobulin preparation and method for its production
Horrow et al.	1991	Hemostatic effects of tranexamic acid and desmopressin during cardiac surgery.
AU2002216042B2 (en)	2006-08-03	Freeze-dried pantoprazole preparation and pantoprazole injection
KR20210141448A (ko)	2021-11-23	안구 표면 질환을 치료하기 위한 안과용 약학 조성물 및 방법
RU2733409C2 (ru)	2020-10-01	Фармацевтические составы, включающие кангрелор высокой чистоты, и способы их получения и применения
JPH04504710A (ja)	1992-08-20	抗血栓組成物
IL189290A (en)	2011-10-31	The composition of the Argatroban
AU2007246046B2 (en)	2010-04-22	Pharmaceutical composition comprising high concentrate of polydatin
CA2575760A1 (fr)	2005-02-10	Betaines specifiques et leurs utilisations
CZ2002291A3 (cs)	2002-10-16	Farmaceuticky stabilní přípravek oxaliplatiny k parenterální aplikaci
Rajendra et al.	2021	Effect of platelet-rich fibrin versus chitosan-based Axiostat hemostatic agent following dental extraction in cardiac patients on antiplatelet therapy: A comparative study
JPH0425255B2 (fr)	1992-04-30
JPH07503719A (ja)	1995-04-20	ヒルジンおよび合成トロンビン抑制因子のための解毒薬
MX2014005006A (es)	2014-11-25	Metodo para preparar solucion de fibrinogeno altamente concentrada y metodo para preparar sellador de fibrina al usar la misma.
AU768543B2 (en)	2003-12-18	Improved enriched platelet wound healant
EP1660070A2 (fr)	2006-05-31	Betaines specifiques et leurs utilisations
US20170096549A1 (en)	2017-04-06	Multivalent cation formulations of partially desulfated heparins
CA3183555A1 (fr)	2021-12-30	Compositions et methodes de traitement d'un choc hemorragique
CA3009458A1 (fr)	2017-07-13	Procedes, compositions et kits pour reduire les adhesions tissulaires
CZ302750B6 (cs)	2011-10-19	Farmaceutická kompozice a ampulka na bázi erythropoietinu a zpusob inhibování mikrobiálního rustu v roztoku obsahujícím tuto látku
TR201804823T1 (tr)	2018-05-21	Hemostati̇k kompozi̇syon
JPH0899899A (ja)	1996-04-16	静脈注射用グロブリン製剤
JP2002060345A (ja)	2002-02-26	血液凝固能異常に係わる疾患の予防・治療剤

Legal Events

Date	Code	Title	Description
2009-08-03	EEER	Examination request
2012-08-03	FZDE	Dead